A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Recurrent Breast Cancer
Interventions: DRUG: Foretinib
Sponsor: NCIC Clinical Trials Group
Collaborators: GlaxoSmithKline